Please login to the form below

Not currently logged in
Email:
Password:

Egalet appoints Stan Musial as CFO

Joins US pharma company after a two-year spell as a start-up consultant

Stan Musial has joined US pharma company Egalet as chief financial officer having spent the past two years as an independent consultant for start-up businesses.

His most recent in-house role was as chief financial officer at Prism Pharmaceuticals, where he served from 2005 to 2011 before its sale to Baxter Healthcare.

Prior to joining Prism, Musial held the position of VP, finance, and chief financial officer for Strategic Diagnostics.

Egalet is a company that specialises in developing abuse-deterrent medication via a platform that prevents easy extraction and deters abuse of drugs through known routes, such as chewing, snorting, and injecting.

The company's president and chief executive Bob Radie said: "The addition of Stan to the management team comes at a critical time as the most advanced products in Egalet's pipeline of abuse-deterrent opioids are nearing phase III.

"Stan's finance experience will be invaluable as we move our pipeline through development and ultimately to the commercial market."

10th May 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics